Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
CORTROPHIN-ZINC is a long-acting injectable corticotropin (ACTH) analog approved in 1955 for adrenocorticotropic hormone replacement and immune-mediated conditions. It works by stimulating the adrenal cortex to produce endogenous corticosteroids, offering sustained activity through zinc hydroxide formulation. The product treats rare endocrine and autoimmune disorders where ACTH replacement or immunomodulation is indicated.
As a legacy injectable with approaching loss of exclusivity, brand team size is likely minimal with focus shifting toward cost management and transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job postings indicate this product represents a legacy maintenance position with limited career growth potential. Professionals joining this brand should expect stable but constrained responsibilities focused on asset management rather than expansion.
Worked on CORTROPHIN-ZINC at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.